FMP

FMP

Enter

CALA - Calithera Bioscience...

Financial Summary of Calithera Biosciences, Inc.(CALA), Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery a

photo-url-https://financialmodelingprep.com/image-stock/CALA.png

Calithera Biosciences, Inc.

CALA

NASDAQ

Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73, as well as CB-668, an orally administered inhibitor of the enzyme IL4I1. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. It also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta. In addition, the company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology; and a license agreement with Antengene Corporation Ltd. for the development and commercialization of CB-708. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

0.02 USD

-0.009 (-45%)

About

ceo

Ms. Stephanie Wong

sector

Healthcare

industry

Biotechnology

website

https://www.calithera.com

exchange

NASDAQ

Description

Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73, as well as CB-668, an orally administered inhibitor of the...

CIK

0001496671

ISIN

US13089P5070

CUSIP

13089P101

Address

343 Oyster Point Boulevard

Phone

650 870 1000

Country

US

Employee

8

IPO Date

Oct 2, 2014

Summary

CIK

0001496671

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

13089P101

ISIN

US13089P5070

Country

US

Price

0.02

Beta

-0.06

Volume Avg.

1.21k

Market Cap

97.45k

Shares

-

52-Week

0.01-0.4999

DCF

2.91

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

0

P/B

-

Website

https://www.calithera.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest CALA News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep